Primary Care of the Patient with Chronic Hepatitis C

Journal for Nurse Practitioners

Volumn 2, Issue 8, 2006, Pages 517-524

  Gardenier, Donald ^a   Alfandre, David ^a  

^a NONE

Author keywords

Comorbidity; disparities; evaluation; hepatitis C; primary care; treatment

Indexed keywords

EID: 33748304302     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2006.05.017     Document Type: Article

References (31)

1. World Health Organization. Hepatitis C Fact Sheet No. 164 (2000). Available at: www.who.int Accessed April 28, 2006.
2. Sturm T., Federman A., Wisnivesky J., and McGinn T. Hepatitis C prevalence and risk factors in an urban primary care practice. J Gen Intern Med. 19 suppl 1 (2004) 157
3. National Institutes of Health. Consensus Statement on the Management of Hepatitis C (2002). Available at: www.nih.gov Accessed April 28, 2006.
4. Larson A., and Carithers R. Hepatitis C in clinical practice. J Intern Med. 249 2 (2001) 111-120
5. Kim W. The burden of hepatitis C in the United States. Hepatology 36 5(suppl 1) (2002) S30-S34
6. Shepard C., Finelli L., and Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 5 9 (2005) 558-567
7. Alter M., Seef L., Bacon B., Thomas D., Rigsby M., and DiBisceglie A. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 141 9 (2004) 715-717
8. Muir A. The natural history of hepatitis C viral infection. Semin Gastrointest Dis. 11 2 (2000) 54-61
9. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 127 10 (1997) 875-881
10. Herrine S. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med. 136 10 (2002) 747-757
11. Rocca L., Yawn B., Wollan P., and Kim W. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med. 2 2 (2004) 116-124
12. Alter M. Prevention of spread of hepatitis C. Hepatology 36 5 suppl 1 (2002) S93-S98
13. Strader D., Wright T., Thomas D., and Seef L. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
14. Shehab T., Orrego M., Chunduri R., and Lok A. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol. 98 3 (2003) 640-644
15. Navarro V., St Louis T., and Bell B. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. J Clin Gastroenterol. 36 5 (2003) 431-435
16. Nguyen M., Herrine S., Laine C., Ruth K., and Weinberg C. Description of a new hepatitis C risk assessment tool. Arch Intern Med. 165 17 (2005) 2013-2018
17. McGinn T., O'Connor N., Gardenier D., and Federman A. Prospective validation of a risk assessment questionnaire for hepatitis C in a primary care setting. J Gen Intern Med. 19 suppl 4 (2006) 122
18. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 140 6 (2004) 462-464
19. Zeuzem S., Franke A., Lee J., Herrmann G., Ruster B., and Roth W. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 24 5 (1996) 1003-1009
20. Liang T., Rehermann B., Seeff L., and Hoofnagle J. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 132 4 (2000) 296-305
21. Manns M., McHutchison J., Gordon S., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
22. Ghany M., and Hoofnagle J. Liver and biliary tract disease. In: Brunwald E. (Ed). Harrison's Principles of Internal Medicine (2001), McGraw-Hill, New York, NY 1707-1711
23. Andriulli A., Persico M., Iacobellis A., et al. Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepat. 11 6 (2004) 536-542
24. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 9262 (2001) 1069-1075
25. McGinn T., Gardenier D., McGinn L., et al. Treating chronic hepatitis C in the primary care setting. Semin Liver Dis. 25 1 (2005) 65-71
26. Sherman K., Rouster S., Chung R., and Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 34 6 (2002) 831-837
27. Sagnelli E., Coppola N., Scolastico C., Mogavero A., Filippini P., and Piccinino F. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 64 3 (2001) 350-355
28. Annemans L., Warie H., Nechelput M., and Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg. 67 1 (2004) 1-8
29. Gardenier D., Alfandre D., Schiano T., O'Connor N., and McGinn T. Primary care based hepatitis C treatment: collaborating to improve access, adherence and outcomes. Hepatology 42 4 supp1 (2005) 675
30. Farley J., Dial D., and Littleton-Kearney M. Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection. J Nurse Pract. 2 1 (2006) 38-45
31. Zickmund S., Hillis S., Barnett M., Ippolito L., and LaBrecque D. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39 4 (2004) 999-1007